VERAXA Biotech secures $27.5M senior secured note to support NASDAQ SPAC merger
What's the deal? VERAXA Biotech AG, a cancer therapy company, has secured a $27.5 million senior secured note to support the closing of its business combination with Voyager Acquisition CorpDealroom has a profile for this one. Try Dealroom →. The funding will advance its pipeline of BiTAC-based therapies toward clinical development.
The business combination, approved by VERAXA's shareholders, is expected to create a publicly traded company listed on NASDAQ under the ticker "VRXA." The transaction is valued at a pre-money equity value of $1.3 billion and includes access to roughly $253 million in cash.
Why now? VERAXA launched its BiTAC platform in 2024, designing it to improve the safety and efficacy of cancer therapies through a combinatorial-gated approach that aims to reduce off-tumour toxicity. The company has nine discovery and development programmes and is actively raising a crossover financing round on top of the $27.5 million note.
With shareholder approval already secured, the SPAC merger appears close to completion — making fresh capital essential to keep clinical timelines on track.
What could go wrong? SPAC mergers in biotech have a mixed record. Companies that go public this way often face intense scrutiny over valuations, and a $1.3 billion pre-money price tag for a firm with no clinical-stage assets carries significant risk. The nine programmes are all in discovery or early development, meaning years of work — and spending — remain before any potential revenue.
Debt financing via a senior secured note also adds obligations that could pressure the balance sheet if the pipeline hits delays.
The signal: VERAXA's SPAC route to NASDAQ underscores how pre-clinical biotech companies continue to tap blank-cheque vehicles to access public markets, even as investor scepticism around SPAC valuations persists. With Voyager Acquisition Corp classified as a "breakout" stage entity on Dealroom and VERAXA's BiTAC platform straddling two of oncology's most active modalities — T-cell engagers and antibody-drug conjugates — the $1.3 billion pre-money valuation is essentially a bet on platform breadth over clinical proof. Whether that premium holds will hinge on how fast VERAXA converts its nine early-stage programmes into clinic-ready assets.
Read more: AInvest
